Firebrick Pharma LimitedASX: FRE

September 2026 Quarterly Activity Report & Appendix 4C

· Issued by Firebrick Pharma Limited via ASX

Filed with ASX · · 7 pages · English

Summary by 6ix AI

The company is entering the US retail pharmacy market with its Nasodine products, following strong online sales growth and participation in a major retail trade expo. Cash operating expenses decreased compared to the previous quarter, primarily due to lower research and development costs, while sales receipts showed a seasonal decline but continued to grow annually. The report includes a compliance statement confirming adherence to accounting standards and provides insights into the company's cash position and activities during the quarter.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

23 October 2026 ASX Announcement September 2026 Quarterly Activity Report Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) is pleased to provide its business activity update for the quarter ending 30 September 2026, along with its Appendix 4C quarterly cash flow report. REVIEW OF QUARTERLY...

Firebrick Pharma Limited on 6ix

Story so far

Earlier from Firebrick Pharma

Later from Firebrick Pharma

All Firebrick Pharma news releases